DEA Marijuana Schedule Change News: What It Means

Where the DEA marijuana schedule change stands right now

Cannabis remains a Schedule I controlled substance under federal law. The DEA proposed moving it to Schedule III in May 2024, the comment period closed that July, and the agency then pushed the question into a formal administrative hearing. That hearing produced a recommended decision from a DEA administrative law judge, and the judge recommended against rescheduling, finding the record did not support a move to Schedule III. The final call now sits with the DEA Administrator, whose order can be appealed in federal court. Until a final rule is signed and published in the Federal Register, nothing has changed on paper, and your dispensary receipt looks exactly the same.

more on this topic

How the process got here

• October 2022: President Biden asked HHS and DEA to review how cannabis is scheduled.
• August 2023: HHS finished its scientific review and recommended Schedule III in a letter to DEA.
• May 2024: DEA published a proposed rule in the Federal Register to move cannabis from Schedule I to Schedule III.
• July 2024: The comment window closed after tens of thousands of filings.
• Late 2024 into 2025: DEA held a formal hearing before an administrative law judge, with designated participants arguing both sides.
• 2025: The judge issued a recommended decision against rescheduling. The Administrator's final order is the next step.

A recommended decision is exactly that, a recommendation. The Administrator can adopt it, reject it, or modify it.

cannabis legal news dea reschedule

What Schedule III would actually change

Schedule III is a big deal for taxes and research, and not much else for the average customer.

dea cannabis regulation changes

• Taxes. Section 280E blocks businesses trafficking in Schedule I and II drugs from deducting ordinary business expenses. Moving to Schedule III would remove that block, which is the single largest financial item in the whole debate.
• Research. Schedule III registration is lighter, so clinical study gets easier to run.
• Federal exposure. Criminal risk drops, but it does not vanish.

What it would not do

• It would not legalize cannabis for adults. Schedule III drugs still require a prescription and DEA-registered handling.
• It would not create a federal medical cannabis program. FDA approval would still be the path.
• It would not override state law or change what a licensed store can sell you.
• It would not settle the interstate commerce questions that states are already bumping into.

I see this confusion constantly at the counter. People hear "rescheduling" and assume it means legalization. It does not. Rescheduling is an administrative move inside the Controlled Substances Act, not a vote to end prohibition.

What I watch next

Two documents matter. One is the DEA Administrator's final order in the Federal Register. The other is any appeal, because a court can send the whole thing back to the agency. Congress is the wildcard, since it can reschedule by statute and skip the agency fight entirely.

For shoppers, the practical answer is dull: your state license still governs the store, and federal scheduling has not changed what sits on the shelf. If you see a headline claiming cannabis is now Schedule III, look for the Federal Register entry first. Until that exists, the news is about process, not status.